ArticlePharmaceuticals (Basel, Switzerland)2023

Trial of a Novel Oral Cannabinoid Formulation in Patients with Hypertension: A Double-Blind, Placebo-Controlled Pharmacogenetic Study.

Ana Batinic et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.